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The relationship between tumour stage, T-lymphocyte subset infiltration and survival was examined in patients with prostate cancer
(n¼80). On multivariate analysis PSA (HR 2.47, 95% CI 1.27–4.83, P¼0.008) and CD4þ T-lymphocyte count (HR 2.29, 95% CI
1.25–4.22, P¼0.008) had independent significance. Increased CD4þ T-lymphocyte infiltration within the tumour was stage
independent and associated with poor outcome in patients with prostate cancer.
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It has long been recognised that disease progression in cancer
patients is not solely determined by the characteristics of the
tumour but also by the host response. Indeed, there is increasing
evidence that both local and systemic inflammatory responses play
an important role in the progression of a variety of common solid
tumours (Coussens and Werb, 2002).
For example, in patients with colorectal cancer, there is good
evidence that the presence of a pronounced lymphocytic infiltra-
tion within the tumour is associated with improved survival (Jass
et al, 1987; Ropponen et al, 1997, Nielsen et al, 1999). More
recently, the ability to identify lymphocyte subsets has led to
renewed interest in the relationship between the tumour inflam-
matory infiltrate and outcome. Indeed, increased infiltration of the
tumour by CD8þ and CD4þ T-lymphocytes has been shown to
be associated with increased survival in patients with colorectal
cancer (Naito et al, 1998; Ali et al, 2004). In contrast, the presence
of an increased infiltration by CD4þ or CD8þ T-lymphocytes
has been associated with decreased survival in patients with renal
cancer (Nakano et al, 2001, Bromwich et al, 2003).
The relationship between lymphocytic infiltration and survival
in other urological cancers, for example prostate cancer, is less
clear. Vesalainen et al (1994) reported that, in a cohort in which
approximately 30% of patients had metastatic disease, tumours
with a dense tumour lymphocyte infiltration were associated with
higher survival rates than tumours with absent or decreased
infiltrates. In contrast, Irani et al (1999) reported that, in patients
undergoing radical prostectomy, an increased inflammatory cell
infiltrate within the tumour was associated with an increased risk
of tumour recurrence.
To date, the relationship between lymphocyte subset infiltration
and survival does not appear to have been assessed in patients with
prostate cancer. The aim of the present study was to examine the
relationship between CD4þ and CD8þ T-lymphocyte infiltration
and survival in patients with prostate cancer.
PATIENTS AND METHODS
Patients
Patients who underwent radical prostatectomy for histologically
proven prostate cancer (n¼11) or who were diagnosed as having
prostate cancer following transurethral resection of prostate for
bladder outflow obstruction (n¼69) were included in the study.
Clinical details recorded included age, stage as described by
Wilkinson and Hamdy (2001), tumour grade as defined by Chodak
et al (1994), circulating concentrations of PSA and haemoglobin at
diagnosis, and subsequent treatment.
All patients were followed up in the Department of Urology. The
date and cause of death was obtained from the cancer registry.
The study was approved by the local ethics committee.
Methods
Immunohistochemistry Blocks from the primary tumour were
fixed in 10% buffered formalin and embedded in paraffin wax. One
representative block of tumour was selected from each patient.
Sections (4mm) were cut and mounted on slides coated with
aminopropyltriethoxysilane. Sections were then immunostained
using the peroxidase-based Envision (Dako, Cambridgeshire, UK)
technique as previously described (Bromwich et al, 2003). The
primary antibody for CD4 was mouse monoclonal (Vector,
Peterborough, UK) and that for CD8 was mouse monoclonal
(Dako, Cambridgeshire, UK).
Morphometry Quantitative analysis of the lymphoid infiltrate was
performed using point counting (Anderson and Dunnill, 1965)
with a random sampling technique. With this method, the volume
occupied by any given component (volume density) is expressed as
a percentage of the total volume of the tissue. A 100-point ocular
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ygrid was used at  400 magnification and 30 fields were counted
per case for CD4þ and CD8þ immunopositive cells.
CD4þ and CD8þ T-cells within the tumour (including both
the cancer cell nests and surrounding stroma) were counted. Any
normal tissue on the slide was excluded from the analysis.
This final method was designed on the basis of a pilot study,
which demonstrated that the volume density of CD4þ and CD8þ
of two observers reached a plateau after 25–30 fields. This pilot
study also demonstrated that CD4þ and CD8þ counts were
equivalent to the CD3þ counts (unpublished data). The observers
(McArdle and Canna) were blinded to the clinical outcome of the
patient.
Statistics
Data are presented as median and range. Where appropriate,
comparison of patient groups was carried out using contingency
table analysis (X
2) and the Kruskal–Wallis test for analysis of
variance. For the purpose of survival analysis T-lymphocyte subset
counts were grouped into tertiles as previously described (Nielsen
et al, 1999). Survival analysis was performed using the Cox
proportional hazard model. Deaths up to August 2003 have been
included in the analysis. Analysis was performed using SPSS
software (SPSS Inc., Chicago, IL, USA).
RESULTS
In total, 80 patients were included in the study. The baseline
characteristics, according to stage, are shown in Table 1. Patients
with metastatic disease were older, had higher circulating
concentrations of PSA and had lower haemoglobin concentrations.
A total of 21 patients underwent radical local therapy (prosta-
tectomy or radical radiotherapy) as primary treatment. The
remaining 59 patients received androgen deprivation therapy.
The median (range) for percentage volume of CD4þ T-
lymphocytes was 0.40 (0.03–1.90). The median (range) for
percentage volume of CD8þ T-lymphocytes was 0.78 (0.27–3.00).
The minimum follow-up was 26 months; the median follow-up
of survivors was 71 months. In all, 41 patients died during follow-
up, 22 of prostate cancer and 19 of intercurrent disease. The mean
cancer specific-survival for those with localised, locally advanced
and metastatic disease was 120, 98 and 66 months respectively
(P¼0.001).
On univariate analysis, advanced stage (Po0.01), elevated PSA
concentrations (Po0.01), decreased haemoglobin (Po0.05) and
increased CD4þ T-lymphocyte counts (Po0.05) were associated
with reduced cancer specific survival (Table 2). On multivariate
analysis PSA (HR 2.47, 95% CI 1.27–4.83, P¼0.008), haemoglobin
(HR 3.48, 95% CI 1.30–9.30, P¼0.013) and CD4þ T-lymphocyte
count (HR 2.29, 95% CI 1.25–4.22, P¼0.008) retained indepen-
dent significance. There was no significant correlation between
PSA concentrations and either CD4þ (P¼0.539) or CD8þ
(P¼0.202) T-lymphocytes. There was also no significant correla-
tion between Gleason scores and either CD4þ (P¼0.246) or
CD8þ (P¼0.409) T-lymphocyte counts.
When those patients with localised or locally advanced prostate
cancer (n¼57) were examined in univariate analysis, only CD4þ
T-lymphocyte count achieved statistical significance (HR 2.88, 95%
CI 1.15–7.22, P¼0.024).
DISCUSSION
The results of the present study show that the presence of an
increase in CD4þ T-lymphocyte infiltrate was associated with
Table 1 Baseline characteristics, according to stage, of patients with prostate cancer
Localised (n¼20) Locally advanced (n¼37) Metastatic (n¼23) P-value
Age group (p70/470) 11/9 22/15 5/18 0.013
Tumour grade (low/intermediate/high) 5/9/5 10/16/11 3/10/10 0.635
PSA (o4/4–10/11–100/4100ngml
 1) 7/5/7/0 4/6/22/3 0/1/12/10 o0.001
Haemoglobin (X12/o12gl
 1) 18/0 28/7 15/7 0.035
% tumour volume
CD4+
a 0.42 (0.03–1.70) 0.40 (0.07–1.90) 0.53 (0.07–1.63) 0.475
CD8+
a 0.87 (0.27–1.70) 0.73 (0.27–3.00) 0.83 (0.27–1.90) 0.882
CD4+ plus CD8+
a 1.30 (0.30–3.13) 1.17 (0.33–4.90) 1.23 (0.50–3.20) 0.801
Treatment (radical local/androgen deprivation) 11/9 9/28 1/22 0.001
Alive/dead (cancer specific/intercurrent) 11/9 19/18 9/14 0.018
2/7 8/10 12/2
aMedian (range).
Table 2 Clinicopathological characteristics in patients with prostate cancer: univariate survival analysis
Patients (n¼80) Hazard ratio (95% CI) P-value
Age group (p70/470) 38/42 2.38 (0.97–5.85) 0.059
Stage (localised/locally advanced/metastatic) 20/37/23 2.99 (1.52–5.88) 0.002
Tumour grade (low/intermediate/high) 18/36/26 1.41 (0.80–2.51) 0.238
PSA (o4/4–10/11–100/4100ngml
 1) 11/12/41/13 2.50 (1.38–4.52) 0.002
Haemoglobin (X12/o12gl
 1) 61/14 3.38 (1.28–8.90) 0.014
Tumour counts
CD4+ T-lymphocyte count (tertiles) 26/28/26 2.03 (1.15–3.59) 0.015
CD8+ T-lymphocyte count (tertiles) 26/28/26 1.46 (0.85–2.52) 0.170
CD4+ plus CD8+ count (tertiles) 26/28/26 1.69 (0.97–2.97) 0.065
Treatment (radical local/androgen deprivation) 21/59 2.08 (0.70–6.17) 0.188
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with prostate cancer. Furthermore, when the analysis was confined
to those patients with localised or locally advanced disease, only
CD4þ T-lymphocyte count predicted survival. These results are
consistent with those of Irani et al (1999) but not with those of
Vesalainen et al (1994).
The reasons for the difference in the results of the present study
and those of Vesalainen et al (1994) are not clear. Both cohorts
included a wide spectrum of disease and both had a similar
proportion of patients with metastatic disease. However, the
apparent discrepancies may reflect differences in methodology,
including the way in which the inflammatory infiltrate was assessed.
Vesalainen and his co-workers assessed the density of tumour
infiltrating lymphocytes on simple staining with haematoxylin and
eosin. Moreover, the type of lymphocyte was not assessed. In
contrast, in the present study, T-lymphocyte subsets were identified
by immunohistochemistry and the density was assessed using a
point counting technique. This approach provided a more objective
assessment and circumvented the problem of variation in distribu-
tion of lymphocytes within an individual tumour.
Why the presence of an increase in CD4þ T-lymphocyte
infiltrate would be associated with poor cancer specific survival in
patients with prostate cancer is unclear since it would seem logical
that an increased T-lymphocyte infiltrate would help control and
even destroy tumour cells. However, it has been suggested that
many of the T-lymphocytes found in tumour beds are inactive and
therefore do not contribute to effective antitumoral immunity.
Indeed, this concept is consistent with the observation that
downregulation of MHC I expression may help tumours cells
escape immune surveillance (Naoe et al, 2002).
In summary, the results of the present study have shown that the
presence of increased CD4þ T-lymphocyte infiltration within the
tumour was associated with poor outcome, independent of stage,
in patients with prostate cancer.
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